互白蛋白在炎症介导的瘤免疫微环境调节中的作用 在结肠直肠癌的发病过程中
Samatha M Jain1, Dikshita Deka1, Alakesh Das1
1Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Chennai, 603103, India.
Digestive diseases and sciences
|June 5, 2023
概括
炎症介导的上皮细胞转变为介质细胞 (EMT) 驱动着结直肠癌 (CRC) 的发展. 准EMT途径为治疗CRC及其相关的免疫微环境调制提供了一个有希望的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 瘤细胞通过表皮细胞转移到介质细胞转移 (EMT) 传播,这是一种受影响于影响细胞外基因基因 (ECM) 和介质细胞激活的基因改变的影响的过程.
- 炎症性细胞因子,如瘤坏死因子和互白蛋白激活转录因子,促进EMT并促进结直肠癌 (CRC) 的发病.
- 持续性炎症是引发癌症的关键因素,炎症性肠道疾病增加了CRC风险.
研究的目的:
- 审查interleukins在瘤免疫微环境的炎症介导调节在结肠直肠癌中的作用.
- 探索EMT和CRC发展之间的联系,重点关注由炎症驱动的途径.
主要方法:
- 关于过去10年发表的研究的文献综述.
- 搜索的数据库包括谷歌学者,PubMed和科学直接.
- 专注于介于炎症的瘤免疫微环境调制中介于CRC中的互白蛋白的作用.
主要成果:
- EMT的特点是上皮细胞标记物减少和中细胞标记物增加,在结直肠癌的发展中观察到.
- 证据证实EMT在人类结肠癌发生中的作用,特别是在慢性炎症的背景下.
- 诸如性结肠炎和克罗恩病之类的炎症状况与较高的CRC发病率有关.
结论:
- NF-κB系统,SMAD/STAT3信号传递,微RNA和Ras-MAPK/Snail/Slug通路都与EMT驱动的结直肠恶性瘤有关.
- 在CRC病变发生过程中,EMT起着重要作用.
- 针对炎症介导EMT的治疗策略为CRC治疗提供了一种新的方法,其中interleukins及其受体是潜在的目标.
相关概念视频
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Inflammatory Response
2.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
204
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
204


